Maine CDC Information
- Health Topics A-Z
- Conferences & Events
- Data and Reports
- Maine CDC Rules
- Public Health Training
- State Health Improvement Plan
- About Us
District Public Health
- Local Health Officers
- Local Public Health Districts
- Public Health Emergency Preparedness
- Statewide Coordinating Council
Information for Health Care Providers
Maine CDC Health Advisory
November 30, 2022
Deauthorization of Bebtelovimab Treatment for COVID-19
FDA today revoked the emergency use authorization for bebtelovimab, a monoclonal antibody therapy. Accordingly, bebtelovimab may no longer be used for COVID-19 treatment in the U.S. With the continued appearance of new variants, COVID-19 infection is now likely to be due to variants resistant to all monoclonal antibody therapies. Healthcare facilities offering COVID-19 monoclonal antibody treatment should explore offering Veklury to patients who cannot receive Paxlovid and should retain outpatient infusion capacity for COVID-19 monoclonal antibody therapies that could be authorized later.
